Inocras Inc. specializes in advanced genomic testing, focusing on whole genome sequencing to provide comprehensive insights into cancer and rare diseases. Their flagship products, CancerVision and RareVision, utilize a whole genome bioinformatics platform that analyzes a patient's unique genomic makeup. This technology allows for a detailed examination of over 99% of an individual's genetic material, significantly surpassing traditional panel testing and whole exome sequencing, which only assess a fraction of the genome. By identifying complex mutations and structural variants often missed by standard tests, Inocras aims to enhance diagnostic accuracy and inform treatment options, ultimately advancing precision health.

The company's approach emphasizes the importance of actionable insights derived from genomic data. Inocras provides user-friendly reports that highlight clinically relevant findings, enabling healthcare providers and patients to make informed decisions regarding treatment and care. Additionally, their services include genetic counseling and connections to clinical trials, ensuring that patients receive comprehensive support throughout their diagnostic journey. By prioritizing rapid turnaround times and maintaining competitive pricing, Inocras is committed to making advanced genomic testing accessible and beneficial for patients, providers, and researchers alike.

United States

Inocras is a company for whole genome sequencing, providing a comprehensive view of a patient's entire genetic profile through WGS analysis and interpretation. Focusing on cancer and rare diseases, we aspire to fundamentally change how the world treats genetically driven diseases with an unsurpassed WGS databank and an integrated platform for generating, collecting, and analyzing genomic data.

Inocras Inc.

Company Details